HER2/neu Receptor Antagonist class drugs
5 results
Herceptin hylecta (trastuzumab and hyaluronidase-oysk)
(Trastuzumab and hyaluronidase-oysk)Genentech, Inc.
Usage: HERCEPTIN HYLECTA is indicated for treating HER2 overexpressing breast cancer in adults. It is used as adjuvant therapy in various regimens for early-stage disease and as a combination or single-agent treatment for metastatic disease. Patient selection is based on FDA-approved diagnostics for trastuzumab.
Kadcyla (ado-trastuzumab emtansine)
(ADO-TRASTUZUMAB EMTANSINE)Genentech, Inc.
Usage: KADCYLA is indicated for treating HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane. It is also used for adjuvant treatment in HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. Patient selection requires companion diagnostic testing.
Margenza (margetuximab-cmkb)
(margetuximab-cmkb)MacroGenics, Inc
Usage: MARGENZA is indicated for the treatment of adult patients with metastatic HER2-positive breast cancer, in combination with chemotherapy, who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Perjeta (pertuzumab)
(Pertuzumab)Genentech, Inc.
Usage: PERJETA is indicated for the treatment of adults with HER2-positive metastatic breast cancer (MBC) in combination with trastuzumab and docetaxel, and for adults with HER2-positive early breast cancer (EBC) in combination with trastuzumab and chemotherapy, both in neoadjuvant and adjuvant settings.
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
(pertuzumab, trastuzumab, and hyaluronidase-zzxf)Genentech, Inc.
Usage: PHESGO is indicated for use with chemotherapy for early breast cancer (EBC) in adults with HER2-positive, locally advanced, or high-risk early stage disease. It is also indicated for treating HER2-positive metastatic breast cancer in adults who have not received prior anti-HER2 therapy or chemotherapy for metastasis.